CURRICULUM VITAE - David F Mobley



CURRICULUM VITAEDAVID F. MOBLEY, M.D., FACS Date of preparation: Jan 10, 2018A.GENERAL INFORMATIONOffice Address:Methodist Urology AssociatesHouston Methodist West HospitalProfessional Building No. 118300 Katy Freeway, Suite 325Houston, Texas, 77094Office Telephone:832-522-8300 Office Fax:832-522-8301Home Address:11327 Noblewood Bend, Houston, Texas 77082Home Telephone:281-493-5555Cell Phone:281-235-5158E-mail:DFMobley@mobleyresearch@Citizenship:USAOptional Information:Birth Date:November 20, 1942 Birth Place:San Francisco, CA. Marital Status:Married Spouse’s Name:Pat MobleyChildren’s Names/Ages:four childrenRace/Ethnicity:CaucasianB.EDUCATIONAL BACKGROUNDDegreeInstitution Name, City, StateDates AttendedYear AwardedB.A.ChemistryUniversity of Arizona9/1960-19655/1965Tucson, ArizonaArizona State University7/1963-8/1963M.D.University of Tennessee9/1965-12/196812/1968Memphis, TennesseeGraduate Certificate in Healthcare Management1/2006-12/200612/2006Executive Education-HealthcareRice University, Houston, TXC.PROFESSIONAL POSITIONS AND EMPLOYMENTPost-doctoral training including residency/fellowshipTitleInstitution Name, City, StateDatesInternshipUniversity of TennesseeCollege of Medicine7/1969-6/1970Memphis, TennesseeSurgery ResidencyBaylor College of Medicine7/1970-6/1971Houston, TexasUrology ResidencyBaylor College of Medicine8/1973-6/1977Houston, TexasAcademic positions (teaching and research)Institution Name, City, StateDatesClinical InstructorDepartment of Pathology7/1967-12/1968University of Tennessee Medical SchoolMemphis, TennesseeAssociate ProfessorInstitute for Academic Medicine7/2014-presentHouston Methodist HospitalHouston, TXAssociate Clinical Professor Weill-Cornell Medical College10/2015-Hospital positions (attending physician, if applicable)TitleInstitution Name, City, StateDatesActive Staff Memorial HermaHermann Memorial City Hospital 8/1977-presentHouston, TXCourtesy Staff Memorial Hermann Katy Hospital 1/1995-2/2012Houston, TXCourtesy StaffSpring Branch Memorial Hospital 2/1997-6/2000Houston, TXActive StaffMemorial Village Surgical Center1/2010-presentHouston, TXActive StaffHouston Methodist Hospital West Houston 5/2011-presentHouston, TXActive StaffHouston Methodist Hospital5/2012-presentHouston, TXEmployment (other than positions listed above)TitleInstitution Name, City, StateDatesTeaching AssistantDepartment of Pathology7/1967-12/1968University of Tennessee, Memphis, TNPhysician Assistant/Medical Clinic of West Memphis1/1969-6/1969PhysicianWest Memphis, AR Major, MCUnited States Air force 8/1971-8/1973UrologistPrivate Practice8/1977-7/2010Houston, TXUrologistTexas Oncology8/2012-12/2011Houston, TXD.LICENSURE, BOARD CERTIFICATION, MALPRACTICE (if applicable)LicensureStateNumberDate of IssueDate of ExpirationTexasD66661971June 30, 2015DEA Number:AM4822210Board CertificationName of SpecialtyBoard Certificate NumberDate of CertificateAmerican Board of Urology7256Feb 5, 1980 Malpractice InsuranceDo you have Malpractice Insurance? YesName of Provider: The Methodist Hospital TrustPremiums Paid By: Houston Methodist Specialty Physician GroupE.PROFESSIONAL MEMBERSHIPS (medical and scientific societies)Member/OfficerName of OrganizationDates HeldFellowAmerican College of Emergency Physicians1974-1978MemberHarris County Medical Society1977-presentMemberTexas Medical Association1977-presentMemberAmerican Fertility Society1978-1990MemberAmerican Society of Andrology1978-1990FellowAmerican College of Surgeons1981-presentMemberAmerican Urological Association1982-presentSouth Central SectionMemberAmerican Society of Undersea Medicine1990-1995MemberAmerican Society for Lasers in Medicine and Surgery1990-2000FellowInteramerican College of Physicians and Surgeons1995-1998MemberEndourological Society1995-2000MemberTexas Medical Foundation-Peer Review Organization2000-2001Corresponding MemberAcademia Peruana Cirugia2000-2002(*some dates are estimated)MemberSociety for Urodynamics and2014-presentFemale Pelvic Medicine (SUFU)F.HONORS AND AWARDSName of AwardYear AwardedOutstanding Urologic Research Award1974, 19775Baylor College of MedicineFirst Place Award: Resident Essay Competition1976South Central SectionAmerican Urological AssociationFirst Place Award 1977Texas Chapter AmericanCollege of Surgeons (surgical research study)Cullen Award for Urologic Research1977Baylor College of MedicineSecond Place Award 1979Western Section American Urological Association (Resident Essay Contest)Physicians Recognition Award1977, 1978, 1980, 1981, American Medical Association1982, 1984, 1987, 1990,1993, 1998, 2000Physician of the Year1992Memorial City Medical CenterG.INSTITUTIONAL/HOSPITAL AFFILIATIONPrimary Hospital Affiliation:Houston Methodist West HospitalOther Hospital Affiliations:Memorial Hermann Memorial City HospitalHouston Methodist HospitalOther Institutional Affiliations:Memorial Hermann Surgery Center Memorial VillageH.EMPLOYMENT STATUSName of Employer: Houston Methodist Specialty Physician GroupEmployment Status: Full-time salaried at Cornell-affiliated hospitalI.CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORTTeaching (list courses and your role)DatesPrivate Practice until 2012Coloplast and American Medical Systems (vendors)1980-2005Proctored penile implant surgeries with physicians in residency (about 25 residents)Academia Peruana de Cirugia3/2000Hospital Nacional Edgardo Rebagliati MartinsLima, PeruProctored penile implant surgeries with 70 doctorsMemorial City Medical Center2002-2004Proctored penile implant surgeries with Junior and Senior medical students from UTMB- Galveston Houston Methodist HospitalI will be involved with training residents and fellows through2012-PresentWeill Cornell, under the auspices of department chair,Dr. Timothy Boone. Clinical CareDatesFull time urologist8/1977-PresentI have areas of special experience in the management of males and females with urinary incontinence and in males with erectile dysfunction. This entails medical and surgical care of urology patients and active clinic trial experience.Administrative Duties (including committees)DatesPopulation Program Action Committee1/1975-12/77Baylor College of MedicineCredentials Committee, Memorial City Medical Center1/1978-12/1979, 1/1981-12/19821/1989-12/1990Emergency Committee, Memorial City Medical Center1/1980-12/1981, 1/1988-12/1991Board of Directors, Bayou City IRB1/1980-12/1988Chief, Urology Section, Department of Surgery1/1981-12/1981, Memorial City Medical Center 1/1983-12/1983, 1/1985-12/1985, 1/1990-12/1990,1/1993-12/1993(each term one calendar yr)Chairman, Emergency Committee, Memorial City Medical Center1/1983-12/1983, 1/1985-12/1985(each term one calendar yr)Director: Center for Overcoming Impotence1/1985-12/1990Memorial City Medical Center, HoustonVice-President Medical Staff, Memorial City Medical Center1/1988-12/1988 (one calendar year)President-Elect, Medical Staff, Memorial Medical Center1991 (Jan-Dec)President, Medical Staff, Memorial City Medical Center1992 (Jan-Dec)Memorial City Medical Center, Disaster Team1990, 1991, 1992(each Jan-Dec)Medical Records Committee, Memorial City Medical Center1991(Jan-Dec)Chairman, Bylaws Committee, Memorial Hospital Memorial City1994 (Jan-Dec)Board of Directors, Memorial Hermann Foundation1/1995-12/2003Investigational Research Review Board, Memorial Hermann Healthcare Hospital System1/1995-12/2000Chairman, Department of Surgery, Memorial Hospital, Memorial City1998 (Jan-Dec)Cancer Committee- Methodist West Houston1/2012-presentEthics Committee- Methodist West Houston1/2012-presentEnhanced Recovery After Surgery (ERAS) Steering Committee3/2015-presentMethodist West HoustonGrant Review Committee- Houston Methodist Hospital5/2015ResearchClinical Research8/1977-presentPrincipal Investigator in approximately 100 clinical trials20% of my professional time has been/is involved in clinical trial work. Research interests include any urological condition; medical, surgical or device-related; both benign and malignant conditions. In addition I am fairly experienced in type II diabetes mellitus research and I am interested in phase II, III and IV studies (reference industry funded studies: #39, 51, 53, 63, 69, 83, 91, 92).I have also been involved in research studies for patients with Postherpetic Neuralgia (reference industry funded studies: 71, 72, 84)Current Percent Effort (%)?????????????????????????????????????????? Does the activity involve WCMCstudents/researchers? No????? Teaching5????? Clinical Care75????? Administration5????? Research15???? ?Total:100Section J. RESEARCH SUPPORT (past and present)Completed Industry Funded StudiesPrincipal Investigator; "A Multicenter Comparison of the Safety and Efficacy of Lomefloxacin vs. Ofloxacin in the treatment of Bacterial Prostatitis Protocol #S69-91-02-196 G.D. Searle & Co. 1974-1977Principal Investigator; "A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Investigate the Long-Term Effects of Finasterde (MK-906) in Patients with Benign Prostatic Hyperplasia." Protocol 048-04/GHBA-909. Merck Research Laboratories/G.H. Besselaar Associates. 1977-1979.Principal Investigator; "A Phase II Dose Ranging Efficacy Study of Oral Zanoterone, A New Steroidal Androgen Receptor Antagonist, In Men with Symptomatic Benign Prostatic Hyperplasia" Protocol #49596-005. Sterling Drug Co. 1980-1982.Principal Investigator; "A Phase II dose Ranging Safety and Efficacy Study of Oral Zanoterone in Subjects with Stage D2 Carcinoma of the Prostate," Protocol #49596-204. Theradex/Sterling Winthrop Pharmaceuticals. 1980-1982Principal Investigator; "Doxazosin vs. Placebo in the management of symptomatic B.P.H." A double-blind placebo-controlled long term study with a long-term open label branch. Pfizer Inc. 1980-1982Principal Investigator; "A One-Year, Multicenter, double-Blind Comparison of the effects of SKF 105657 vs. Placebo in the treatment of symptomatic B.P.H. With Six Month Untreated Follow-Up," Protocol 105657/018. Smith Kline Beecham Pharmaceuticals. 1980-1982.Principal Investigator; "A Randomized Double-Blind Placebo-Controlled Parallel Study to Assess the Efficacy and Safety of Four Dose Levels of RS-15385 in Men with Erectile Disorder." Protocol #92CE28-0606. Syntex Development Corp. 1982-1984Principal Investigator; "A Twenty-Six Week, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension Using Doxazosin Tablets for the Treatment of Benign Prostatic Hyperplasia," Protocol #92CE28-0606 Pfizer Central Research, Inc. 1982-1984.Principal Investigator; "A Randomized Pilot Study to Assess the Efficacy and Safety of Two Oral Dose Levels of Delaquamine HCl in Men WithErectile Disorder." Protocol #DELS2282-Syntex Development Research. 1982-1984.Principal Investigator; "A Phase II Dose Finding Placebo Controlled Study of Four Dose Levels of YM617 in Patients with Signs and Symptoms of Benign Prostatic Hyperplasia." Protocol #YM617US90-01. Yamanouchi Pharmaceutical Company L\, Ltd./Oxford Research International Corporation. 1983-1985.Principal Investigator; "Ro 23-6240 (Fleroxacin) in Uncomplicated Urinary Infections in Women. A Randomized, double Blind, Prospective Study Versus Ciprofloxacin" Protocol #N3606B. Hoffman-La Roche. 1983-1985.Principal Investigator; "A Sixteen-Week, Double-Blind, Placebo-Controlled Dose Response Study Using Doxazosin Tablets For the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients," Protocol #90CE28-0488. Pfizer, Inc. New York. 1983-1985.Principal Investigator; "A Phase II/III Open-Label, Long-Term, Follow-up Safety Study of Oral Zanoterone in Men with Symptomatic Benign Prostatic Hyperplasia." Protocol #49496-006. Sterling Winthrop Pharmaceuticals Research Division. 1983-1985.Principal Investigator; "A One-Year Multicenter, Double-Blind Comparison of the Effects of Once-Daily Dosing with Three Dose Levels of SK&F 105657 or Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia with Six-Month Untreated Follow-up," Protocol # 15385S2280. Syntex Development Research. 1984-1986.Principal Investigator; "A Two-Year, Open-Label, Multicenter Study of Oral Epristeride 80mg.Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #10560/051. SmithKline Beecham Pharmaceuticals. 1984-1986.Principal Investigator; "A One-Year, Open Label, Multicenter Study of Oral Epristeride 80mg. Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #105657/051. SmithKline Beecham Pharmaceuticals. 1984-1986.Principal Investigator; Part A - "Clinical Efficacy and Safety of Two Doses of Tolterodine Compared to Placebo, A Phase III Randomized, Double Blind, Multinational Study in Patients With Detrusor Over-Activity and Symptoms of Frequency, Urge Incontinence and Urgency." Part B - Long-Term Safety, Tolerability and Clinical Efficacy of Tolterodine-A phase III, Open, Multinational Study in Patients with Detrusor Over-Activity and Symptoms of Frequency, Urge Incontinence, and Urgency." Protocol 940ATA009-923. Pharmacia, Inc. 1985-1987.Principal Investigator; A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Evaluation of GII98745 and Finasteride in Subjects with Benign Prostatic Hyperplasia" Protocol #ARIA2001. Glaxo Wellcome, Inc. 1985-1987.Principal Investigator; "A Five-Month, double Blind, Placebo-Controlled, Randomized Multicenter Cross-Over Study of the Effects and Safety of Testosterone Transdermal System (TTD System) in Men Presenting with Sexual Dysfunction and Serum Testosterone Levels <350ng./dl/" Protocol #TT1000/002. SmithKline Beecham Pharmaceuticals/Clinical Trials, Inc. 1985-1987.Principal Investigator; "A Double-Blind, Randomized, Placebo-Controlled Parallel Group, Multicenter, Flexible Dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Patients with Erectile Dysfunction" Protocol #148-103 (CBI-1171). Pfizer/Corning Besselaar. 1985-1987.Principal Investigator; "A Double-Blind, Placebo-Controlled, dose-Ranging Clinical Evaluation of G1231818 In Subjects with Benign Prostatic Hyperplasia" Protocol #A1A2001,, Glaxo Wellcome Inc/Clinical Trials Research, Inc. 1985-1987.Principal Investigator; "A Phase III Efficacy and safety Study of Three Fixed doses of Apomorphine SL Tablets Versus Placebo in the treatment of Male Erectile Dysfunction" M96-470, Tap Holdings./IBRD. Rostrum Global. 1986-1988.Principal Investigator; "The Maximum Tolerated and Minimum Effective Dose of OROSSYMBOL 226 \f "Symbol" in the Treatment of Patients with Urge or Mixed Urinary Incontinence." C95-049-02. ALZA Corporation. 1986-1988.Principal Investigator; "A Double-Blind, Placebo-Controlled Crossover Design Study to Evaluate the Effects of Three Single Doses of a Selective Alpha-1 Adrenoreceptor Antagonis RS-100975-190 on Peak Urinary Flow Rate in Men with Benign Prostatic Hyperplasia (BPH)" S2679. Roche Bioscience. 1986-1988.Principal Investigator; "A Double-Blind, Placebo Controlled, Parallel, Fixed Dose Study of Sertraline In The Management of Premature Ejaculation. Protocol 96CE21-0702. Pfizer Pharmaceuticals. 1987-1989.Principal Investigator; Prospective Study for Urethrin Implant used in the Treatment of Urinary Incontinence. Protocol G930198. Mentor Urology. 1987-1989.Principal Investigator; Evaluation of the Safety and Efficacy of MUSE plus the ACTIS Venous Flow Controller in Men with Erectile Dysfunction. Protocol AV-01. Vivus, Inc. Menlo Park, CA. 1987-1989.Principal Investigator; An Open-Label trial of Oral Phentolamine in Patients with Mild to Moderate Erectile Dysfunction. Protocol ZON 303. Zonagen, Inc. The Woodlands, Texas. 1987-1989.Principal Investigator: A prospective Study of Mentor Alpha-1 Penile Implant in Men with Organic Impotence. Mentor Urology. Santa Barbara CA. 1988-1990.Principal Investigator; A Prospective Study of the Efficacy and Reliability of the DP9010 Inflatable Penile Prosthesis. A Phase III Study. American Medical Systems. Minnetonka, MN. 1989-1991.Principal Investigator; A Phase III Efficacy and Safety Study Comparing Escalating Doses of Apomorphine SL to 5 or 6 mg. Doses of Apomorphine SL or Placebo in the Treatment of Male Erectile Dysfunction. Protocol Number M97-763. Tap Holdings, Inc. 1989-1991.Principal Investigator; Benign Prostatic Hyperplasia (BPH): Effectiveness of Terazosin Therapy in Patients Treated With Finasteride. Abbott/SCP Principal Investigator: Duloxetine versus placebo in the relief of stress incontinence. Protocol FIJ-MC-SAAW(a). Eli Lilly Inc. 1989-1991.Principal Investigator; Efficacy and Safety of Alfuzosin Once Daily Tablets at Two dosage Levels Versus Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia. Protocol 2650. Synthelabo. 1989-1991.Principal Investigator; A Randomized, Double-blind Comparative trial Of Biclutamide 150mg. Versus Placebo Each in Combination with Castration as Second-line Therapy in Patients with Asymptomatic Metastatic Prostate Cancer. Protocol 7054US/0007. Zeneca Pharmaceuticals. 1990-1992.Prinicpal Investigator; A Dose-Range Finding Double-Blind, Randomized, Placebo-controlled, Multicenter, Active Comparator Study to Determining the Effect of L-753099 in Postmenopausal Women with Predominately Urge Urinary Incontinence. Protocol 011-00Draft. Merck Research Laboratories. 1990-1992.Principal Investigator; A Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Fixed-dose, Dose-Ranging Study to Assess the Safety and Efficacy of Daily Administration of a Single Oral Dose of YM905 in male and Female Patients with Urge Urinary Incontinence. Protocol 905-CL-006. Yamanouchi USA, Inc. 1990-1992.Principal Investigator; Long term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support. Project 7081 Protocol 9912. Mead Johnson Nutritionals. 1990-1992.Prinicipal Investigator; A Study on Incidence of Autoinflation with the American Medical Systems 700 Series Inflatable Penile Prosthesis. Protocol AMS99-003. American Medical Systems. 1990-92.Principal Investigator; A randomized, double-blind, placebo-controlled, multi-center, fixed dose, parallel group, 3-month comparison study to investigate the efficacy and safety of the phosphodiesterase Type V inhibitor BAY 38-9456 in males with erectile dysfunction and diabetes mellitus. Bayer Pharmaceutical Divison. West Haven CT. 1991-92.Principal Investigator; Double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of darifenacin versus tolterodine in the treatment of subjects with overactive bladder. Protocol A1371001 Pfizer Pharmaceuticals, NY. 1991-93.Sub-Investigator; A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutinin Transdermal Systems versus Tolterodine Long-Acting Capsules in Patients with Overactive Bladder. Protocol O00011. Watson Pharmaceuticals. Salt Lake City UT. 1991-93.Principal Investigator; A Randomized, Placebo-Controlled, Double-Blind, Parallel Design, Phase 3 Trial of the Efficacy and safety of Alprox-TD in Male Patients with Erectile Dysfunction. Protocol No MED 2000-DDS NexMed, Inc. 1991-93.Principal Investigator; Protocol FIJ-MC-SBAY Long Term Monitoring of Safety in Subjects Treated with Duloxetene for Stress Urinary Incontinence. Lilly Pharmaceuticals. Indianapolis, IN. 1992-94.Principal Investigator; Trial 526.26, A two phase, double blinded, randomized, parallel group design, multicenter study of Flomax capsules, 0.4 mg. Versus placebo in male patients with acute urinary retention related to benign prostatic hyperplasia. Boehringer Ingelhem, Inc. 1993-95.Principal Investigator, A 6-Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group, Multicenter, Multidose Study of the Efficacy and safety of KW-7158 in Patients with Overactive Bladder Symptoms of Increased Urinary Frequency, Urgency and Urge Incontinence. Study 71580INT-001. Kyowa Pharmaceutical, Inc. 1994-96.Principal Investigator; A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Rofecoxib in Decreasing the Risk of Prostate Cancer. Protocol MK-0966-201. Merck, Inc. 1994-96.Principal Investigator; A Randomized, Placebo-Controlled, Parallel Group Study of the efficacy and safety of Dutasteride 0.5 mg. Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. The REDUCE Trial. Protocol ARI4006. 1997-99.Principal Investigator; A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 20mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 20mg vardenafil. Study #BAY38-9456/100497. Bayer. 1997-99.Principal Investigator; A double blind, placebo controlled, randomized US/Latin America study to evaluate the effect of tolterodine prolonged release on nocturia in patients with symptoms of overactive bladder. Protocol 583E-URO-0084-037, IND#56,406. Pfizer/Pharmacia. 1997-99.Principal Investigator; A six month open label, randomized multi-center study to evaluate the comparative efficacy and safety of oral Famvir in the episodic and suppressive treatment of recurrent genital herpes. Protocol CFAM810A US07, Novartis Pharmaceuticals. 1997-99.Principal Investigator; A Multi-center, double-blind, Randomized, Active-Controlled Parallel Group Study to Evaluate the Lipid-altering Efficacy of MK-0767 in Patients with Type 2 Diabetes and Dyslipidemia. Protocol 034. Merck Inc. 1997-99.Principal Investigator; A Multicenter, Open Label, Flexible Dose Study To Investigate the Use of Patterns of Viagra (sildenafil citrate) and the Ability of Investigators to Further Optimize Subject Satisfaction with Viagra Through Customized Instruction. Protocol A1481179. Pfizer, Inc. 1997-99.Principal Investigator; A Multi-center, Double-blind, Randomized, Active Controlled Parallel Study in Patients with Type 2 Diabetes to Evaluate the Cardiac and Metabolic Effects of MK-0767. Protocol #018 Merck Pharmaceuticals Inc. 1997-99.Principal Investigator; A Randomized, double-blind, Multicenter, Placebo-controlled, Parallel group study to Evaluate the Efficacy and Safety of Valsartan (320mg.) and Hydrochlorthiazide (12.5 and 25mg) combined and alone, Valsartan 160 mg. and Valsartan 160 mg/Hydrochorthiazed 12.5 mg in Hypertensive Patients. Study No CVAH631C2301. Novartis Pharmaceuticals Corporation. 1997-99.Principal Investigator; Study of Duloxetine DCl in women of Different Demographic characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Protocol F1J-US-SBCD. Eli Lilly & Co. 1997-99.Principal Investigator; An Open-Label stuidy to Evaluate the Efficacy and Safety of Tadalafil Aministered “On Demand” to Men of Various Populations with Erectile Dysfunction. Protocol No.: H6D-MC-LVFN(b) Lilly Icos. 1997-99.Principal Investigator; An Open-Label Study of the efficacy and safety of 5 and 10 mg Vesicare (Solifenacin Succinate) in Patients with Overactive Bladder Symptoms. Protocol 905-UC-007. Yamanouchi Pharma America, Inc. 1997-99.Principal Investigator; a Phase 2b, Multi-center, double-blind, Placebo-controlled, Parallel group Dose Response Study to Assess the Efficacy and safety of Oral UK-390,957 in Men With Premature Ejaculation. Pfizer Inc. Protocol #A3871022. 1998-2000.Principal Investigator; A Randomized, double-blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin 20 gm in the Primary Prevention of Cardiovascular events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels C-Reactive Protein. Protocol No 4522US/0011. AstraZeneca. 1998-2000.Principal Investigator; A Randomized, Double-Blind, Placebo controlled, Four Arm Study to Evaluate the Clinical Efficacy and Safety of Tolterodine ER 4mg in Men Who Have Frequency and Urgency, With or Without Urinary Urge Incontinence, With or Without Bladder Outlet Obstruction. Protocol #A621120. Pfizer Inc. 1998-2000.Principal Investigator; A Phase 2, 8 week, Multi-center, Randomized Double-blind, Placebo controlled, Parallel; Group Study evaluating the Efficacy, Tolerability and Safety of (S,S)-REBOXETINE (PNU-165442G) for Stress Urinary Incontinence in Women. Protocol A6061023. Pfizer Pharmaceuticals, Inc. 1999-2001.Principal Investigator; A 12 week, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy of Enablex? (darifenacin) 15 mg OD on increase in warning time, the time from first sensation of urgency to voiding, in patients with Overactive Bladder (OAB). Protocol DAR328A2401. Novartis Pharmaceuticals Corp. 1999-2001.Principal Investigator; A multicenter, randomized, double blind study of MK-0431 in patients with Type 2 Diabetes Mellitus who have inadequate Glycemic Control. Protocol 023. Merck & Co., Inc. 1999-2001.Principal Investigator; A Phase 2 multicenter, open label, long term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. Protocol A3871028. Pfizer. 2000-2002.Principal Investigator; A Phase 2B, multicenter, double blind, placebo controlled, flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. Protocol A3071029. Pfizer. 2000-2002.Principal Investigator; A multicenter, double blind, randomized, placebo controlled, parallel group, dose ranging of L-000796568 in postmenopausal women with overactive bladder. Protocol 024. Merck & Co., Inc. 2001-2003.Principal Investigator; A double blind, multicenter, randomized, placebo controlled study of safety and efficacy of trospium chloride 60 mg modified release capsules versus placebo, once daily, for 12 weeks followed by a 9 month, open label treatment phase in patients with overactive bladder. Protocol IP631-022. Indevus Pharmaceuticals, Inc. 2001-2003.Principal Investigator; A multicenter, double blind, placebo controlled, flexible dose study with an open label phase to assess the efficacy of sildenafil citrate on erectile function and intercourse satisfaction and validate the sexual experience questionnaire and investigate treatment responsiveness to sex-q in men with erectile dysfunction. Protocol 1481236. Pfizer. 2001-2003.Principal Investigator; A multicenter, randomized, double-blind, placebo controlled, Phase 3 trial to evaluate the efficacy and safety of saxagliptin (BMS-477118) in combination with thiazolidinedione therapy in subjects with Type 2 Diabetes who have inadequate glycemic control on thiazolinedione therapy alone. Bristol-Myers Squibb. 2002-2004.Principal Investigator; A two-arm, open label, randomized, multi-center pharmacokinetic and long term safety study of intramuscular injections of 750 mg and 1000 mg testosterone undecanoate in hypogonadal men. Indevus Pharmaceuticals, Inc. 2003-2005.Principal Investigator; [S,S]-Reboxetine dose-range finding trial: A 16-week, randomized, double blind, placebo and pregabalin controlled, multi-center trial of [S,S]-reboxetine in patients with Postherpetic Neuralgia (PHN). Pfizer, Inc. 2004-06.Principal Investigator; An open label extension trial assessing the safety and tolerability of [S,S]-Reboxetine in patients with Postherpetic Neuralgia (PHN). Pfizer, Inc. 2004-2006.Principal Investigator; A randomized, double blind, placebo controlled, parallel group, multicenter safety and efficacy, Phase 4 study of Vesicare? (Solifenacin Succinate) or placebo in combination with tamsulosin hcl for the treatment of residual OAB symptoms of urgency and frequency in men. Astellas Pharma US, Inc. 2005-2007.Principal Investigator; A four-arm, randomized, double blind, parallel, placebo controlled, exploratory study of pagoclone 0.15 mg, 0.30 mg, and 0.60 mg in men with primary premature ejaculation. Indevus Pharmaceuticals, Inc. 2005-2007.Principal Investigator; A multicenter, double blind, placebo controlled study of the efficacy and safety of daily dosing with oxybutinin topical gel to treat the symptoms of overactive bladder. Watson Laboratories, Inc. 2006-2008.Principal Investigator; A randomized, double blind, placebo controlled Detrol LA “Add-On” to alpha blocker study in men with persistent overactive bladder symptoms of urinary frequency and urgency with/without urgency incontinence after previous monotherapy with alpha blocker. Pfizer, Inc. 2006-2008.Principal Investigator; A multicenter, placebo controlled, randomized, double blind, dose ranging study of SVT-40776 in patients suffering from overactive bladder syndrome (OAB). Salvat Laboratorios. 2006-2008.Principal Investigator; A randomized, double blind, placebo controlled, multi center, Phse 3 study of denosumab on prolonging bone metastasis free survival in men with prostate cancer. Amgen, Inc. 2007-2009.Principal Investigator; Lipid Treatment Assessment Project 2 (L-TAP2). Pfizer, Inc. 2008-2010.Principal Investigator; A 12-week, multicenter, open label, single arm study to evaluate the effects of fesoterodine on treatment satisfaction and symptom relief in overactive bladder patients. Pfizer, Inc. 2009-2011.Principal Investigator; 12-week, randomized, double blind, double dummy, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. Pfizer, Inc. 2009-2011.Principal Investigator; A Phase 3 randomized, open label study of CG1940 CG8711 versus docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer who are chemotherapy na?ve. Cell Genesys, Inc. 2009-2011.Principal Investigator; A multicenter, randomized, open label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with vildagliptin 100 mg qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community based practice setting. Novartis Pharmaceuticals Corp. 2010-12.Principal Investigator; [S,S]-Rebozetine add-on trial: A randomized, double blind, placebo controlled, multicenter trial of [S,S]-Reboxetine in patients with postherpetic neuralgia (PHN) concomitantly treated with pregabalin. Pfizer, Inc. 2010-12.Principal Investigator; A randomized, double blind, parallel group study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celocoxib with naproxen and ibuprofen. Pfizer, Inc. 2010-12.Principal Investigator; A Phase 3 randomized, open label study of docetaxel in combination with CG1940 and CG8711 versus docetaxel and prednisone in taxane-na?ve patients with metastatic hormone refractory prostate cancer with pain. Cell Genesys, Inc. 2010-12.Principal Investigator; A Phase 2, randomized, double blind, parallel group, placebo controlled, multicenter, study to evaluate the safety of the co-administration of solifenacin succinate with 0.4 mg tamsulosin hydrochloride OCAS (TOCAS) using urodynamics in male subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO). Astellas Pharma US, Inc. 2010-12.Sub-Investigator; A randomized Phase 2 study of the anti-angionesis agent AG-013736 in combination chemotherapy and bevacizumab in patients with metastatic colorectal cancer preceded by a Phase 1 portion. Pfizer, Inc. 2010-12.Sub-Investigator; A randomized, double blind Phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. Pfizer, Inc. 2010-12.Principal Investigator; PROLIEVE;Post-Marketing Study Using Prolieve for the treatment of BPH. Boston Scientific Corp. 2009-2012.Principal Investigator; HARMONY 4 GLP112754; A Randomized, Open-Label Parallel Group Multicenter Study to Determine the Efficacy and Long Term Safety of Abiglutide Compared with Insulin in Subjects ith Type 2 Diabetes Mellitus. GSK. 2011-2012.Principal Investigator; LX4211.1-202DM; A Phase II, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination with Metformin in Subjects with Type II Diabetes Mellitus. Lexicon Pharmaceuticals. 2011-2012.Current Protocols (Industry Funded):Principal Investigator; NX02-0018;Phase III Multicenter Prospective Randomized Parallel Group Placebo Controlled Double-Blind Clinical Evaluation of NX-1207 for the Treatment of BPH. Nymox Pharm. 2011-ongoing (1% effort). $27,076.Principal Investigator; NX02-0020;Phase III Multicenter Open Label Safety Evaluation of Re-injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 years apart. Nymox Pharm, 2011-ongoing. (2% effort) $25,763.55Principal Investigator; 905-UC-050; A randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to assess Efficacy and Safety of VESIcare (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy. 2011-ongoing. (2% effort) $7,750.00Principal Investigator; SPC-120-DB-201101; A Randomized, Double-Blind, Placebo-Controlled Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients with Nocturia. Serenity Pharmaceuticals; 2010-ongoing. (2% effort) $45,860.00Principal Investigator; ZA-203 Ext REPROS; A Randomized, Double-Blind, Placebo-Controlled Parallel, Multicenter, Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels. Repros Therapeutics, Inc. 2010-ongoing (2% effort) $51,996.00Principal Investigator; HARMONY 3 GLP112753; A Randomized, Double Blind , Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide. GSK. 2011-ongoing. (2% effort) $118,472.00Sub-Investigator; (P.I.: Brian Miles, M.D.) STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy. Protocol MDV3100-09. MEDIVATION, Inc. 2011-ongoing. (2% effort) $23,396.90Principal Investigator: 178-1008-A Phase 4, double blind, randomized, placebo controlled, multicenter study to evaluate the efficacy, safety and tolerability of mirabegron in men with overactive bladder symptoms while taking tamsulosin for LUTS due to BPH-PLUS- AstellasPrincipal Investigator; Synergy 178-CL-101: A randomized, Double-Blind, Parallel-Group, Placebo-and Active-Controlled Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder. Protocol #178-CL-101 and 102 v2. Astellas Pharma. 2014-ongoing. (2% effort) $88,675.00Pending Protocols:Principal Investigator; A phase 2 randomized, double-blind, placebo-controlled, study of MR901 in patients with LUTs due to BPH. Mundipharma Research Lts. Cambridge UK, 2015 (Methodist IRB approval pending as of April 15, 2015)(All clinical trials listed have been industry-supported.)Non-industry – supportedSub Investigator: Miles, B, Mobley, D. Quality of Life and clinical outcomes in men with prostate cancer treated with HIFUK. EXTRAMURAL PROFESSIONAL RESPONSIBILITIESExecutive Director; The Impotence Foundation Santa Barbara, California1989-1995Host/Moderator: Health Talk Houston, Medical Television Show1989-1992Executive Director: The Incontinence Foundation. Goleta, California1989-1992Regional Medical Director: Impotence Institute of America; Washington D.C.1992-1996Host: “Houston Methodist Health Hour” Station AM700 KSEV Radio, Houston1992-presentConsultant, American Foundation for Urologic Diseas, Baltimore, MD1993 Board of Trustees, Memorial Foundation, Houston Texas 1994-2001Board of Advisors- Managed Care in Urology Published by Bard In.1995Editorial Board: Journal of Men’s Health 2000-2001Editorial Board: Medical Aspects of Human Sexuality1991-1992Manuscript Reviewer: Journal of Asian Andrology2014-presentEditorial Board: Asian Journal of AndrologyApplication in processINVITED PRESENTATIONS-SELECTED:Patch Graft CystoplastySouth Central Section A.U.A.San Juan, P.R.September 27, 1975 (First Place Award)In-Situ Ureteral GraftSouth Central Section A.U.A.September 27, 1975San Juan Puerto RicoErythromycin in Treatment of ProstatitisKimbrough Annual SeminarSan Antonio TX October 5-9, 1975Experimental Model for VaricoceleAmerican Urological AssociationLas Vegas NVMay 17-20, 1976Replacement of a Large Segment of Ureter with Autologous Ureteral Graft.American College of SurgeonsDallas, TXOctober 17-21, 1977 (First Place Award)Evaluation of the Impotent MaleAASECT New Orleans, LANovember 11, 1978Evaluation and Treatment of Impotence: Experience with the Inflatable Penile ProsthesisSouthern Medical AssociationAtlanta, GA November 12, 1978Treatment of ProstatitisExhibitSouthern Medical AssociationLas Vegas NVNov 2-5, 1979Indanyl Carbenicillin in the Treatment of Chronic Bacterial ProstatitisDelaware Academy of MedicineWilmington DEMay 6, 1980Fertility and VasectomyAssociasion Para Estudio Reproduccion HumanaMonterrey MexicoAugust 10-12, 1980Carbenicillin vs. TMP-SMX in the Treatment of ProstatitisScientific ExhibitAmerican Academy of MicrobiologyDallas TXMarch 1, 1981Chronic ProstatitisPennsylvania State Medical SchoolHershey PAFebruary 15, 1982Surgical Treatment of Male ImpotenceTexas Psychological Association Annual MeetingHouston TXDecember 1981Applied Model for Effective Diagnosis and Treatment of Impotence A Team Approach and Algorithm(Presented with Avi Raphaeli, Ph.D.)Sixth Annual World Sexology ConferenceWashington DCMay 25, 1983Percutaneous Removal of Renal CalculiPresented to Association of Surgical Technologists, Inc.Body Human SeminarHouston TXSeptember 15, 1984A Sixteen-week, Double-Blind, Placebo Controlled, Dose-Titration Study Using Doxazosin Tablets For the Treatment of BPH in Normotensive Pts.Presented to American Urological Association Meeting, in conjunction withDr. J. Gillenwater. San Antonio TX. May 1993.Doxazosin: Improved Urodynamics and Symptomatology in Normotensive BPH Patients Presented with Jay Gillenwater, M.D.International Prostate SymposiumParis, France, July 1993Update in the Management of Benign Disease of the ProstateA national teleconference videoSponsored by the National Institutes of HealthBethesda, MD October 26, 1993The Effect of Zanoterone, a Steroidal Androgen Receptor Agonist in Men with Benign Prostatic Hypertrophy.Presented to American Urological Association MeetingSan Francisco, CA May 15, 1994Physicians on a Tightrope.Presented to Annual Meeting Oklahoma Urological AssociationAston, OK, April 16.1994Doxazosin in the Management of Symptomatic BPH. Results with 566 Results with 566 Patients.Presented to the Annual Meeting American Urological AssociationSan Francisco, CA May 16, 1994Safety of Doxazosin in the Treatment of BPHPresented to Annual Meeting, American Urological AssociationLas Vegas, NV April 24, 1995Doxazosin in the Management of Benign Prostatic HyperplasiaPresented to 3rd International Consultation on BPHMonaco, June 27, 1995BPH, Past, Present and Future:Presented to South Central Section, American Urological AssociationAnnual MeetingKansas City, MO. September 10, 1995Medical Management of Benign Prostatic HyperplasiaModerator of SymposiumSpeakerPresented to primary care symposium/The PROTECT systemBroken Arrow, OK. Sept 21, 1995.Educating the Primary Physician on Evaluation and Treatment of BPH Patients Nuances of Newer Therapies for BPHPresented to Annual Kibrough Urological SeminarWashington, DC. November 30, 1995Doxazosin in Patients with BPH: Effects as a Function of Baseline Disease Severity.Presented to Annual Meeting American Urological AssociationOrlando FL. May 7, 199626-Week Efficacy and Safety of Doxazosin in the Treatment of Benign Prostatic HyperplasiaPresented to: European Association of Urology Annual MeetingParis, France. Sept 1, 1996Visiting Professorship: Techniques Of Penile Implant SurgeryHospital Provincial, Oviedo, Spain. September 15, 1997Visiting Professorship: Techniques of Penile Implant SurgeryLecture in Pre and Post-operative CareHospital Carlos Alla Malaga, Spain. September 16, 1997Visiting Professorship/Urology: Techniques of Infrapubic vs. Penoscrotal Approach in Penile Prosthesis SurgeryHospital Universario de GranadaGranada, Spain. September 17, 1997Visiting Professorship/Urology: Techniques in Management ofPost Infection Implant Surgery.Hospital Universario del Rio Herrero Valladolid Spain. September 18, 1997Visiting Professorship; Hospital General De Jerez. Teaching PenileProsthesis Surgery and Lecturing on Trouble-Shooting Penile ImplantSurgery. Jerez, Spain. November 3, 1997Visiting Professorship; Hospital General de Albacete; Teaching PenileProsthesis Surgery; Lecture: Complications of Implant Surgery.Albacete, Spain. November 4, 1997Visiting Professorship; Hotel Doce de Octubre.Teaching Penile Prosthesis Surgery; Lecture: Avoiding and ManagingPenile Prosthesis Problems. Madrid Spain. November 5, 1997Visiting Professorship; Hospital Virgen del Mar. Madrid Spain. SurgicalManagement of the Difficult Implant Patient. Treatment of Severe Fibrosis. Madrid, Spain. November 6, 1997The Importance of Exercise in the Elderly Patient. Presented as Keynote address to Senior Olympics Houston, TX. March 11, 1999Experience with the Harmonic Scalpel In Radical Prostatectomy. Presented to Academia Peruana Conference. Lima, Peru. March 7, 2000Influence Sling Procedure in the Management of Stress Incontinence.Presented to Academia Peruana Conference. Lima, Peru. March 7, 2000Use of Cox-2 Inhibitors in Urology. Presented to Department of Urology. Louisiana State University Medical School. Shreveport, LA. March 28, 2001The Influence Sling Procedure in the Treatment of Female Stress Incontinence. Continuing Education Course. Hospital Central Militar. Mexico City, Mexico. April 21, 2001Visiting Professorship: Hospital Central Militar, Mexico City. Surgical Demonstration of Female Sling Procedures. Mexico. April 21, 2001The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Atlanta, GA. June 22, 2002Update on BPH/LUTS. Presented at Below the Beltline Conference. Houston TX. Feb 28, 2015Early History of the inflatable penile implant, from someone who was there. Invited faculty. To be presented to 21st Annual Scientific Meeting of Sexual Medicine Society of North America. Las Vegas, NV. November 20, 2015. UNITED STATES PATENT:Patent number 4043346August 23, 1977Urethral Catheter. Developed with Dr. Neil Baum and Baylor College of Medicine.L.BIBLIOGRAPHYPeer Reviewed ArticlesMobley DF. Hafnia septicemia. South Med J. 1971 Apr;64(4):505-6. No abstract available. PMID: 5552027Mobley DF. Familial vesicoureteral reflux. Urology. 1973 Nov;2(5):514-8. PMID: 4767170Mobley DF. Erythromycin plus sodium bicarbonate in chronic bacterial prostatitis. Urology. 1974 Jan;3(1):60-2. No abstract available. PMID: 4591412David F. Mobley. Chronic Prostatitis. South Med J.?1974 Feb;67(2):219-24. Mobley DF. Left spermatic vein cortisol in subfertile men with varicocele. Urology. 1974 Apr;3(4):461-4. No abstract available. PMID: 4822695Mobley DF, Griffith DP. Acute urinary retention in a child due to procolpos and pyometrium. Urology. 1974 Jun;3(6):784-6. No abstract available. PMID: 4836345Baum N,?Mobley?DF,?Carlton CE Jr. Ureteral?replacements. Urology.?1975 Feb;5(2):165-71.Mobley DF. Semen cultures in the diagnosis of bacterial prostatitis. J Urol. 1975 Jul;114(1):83-5. PMID: 1095783Mobley DF. Metastatic carcinoma of prostate masquerading as abdominal aortic aneurysm. Urology. 1975 Jun;5(6):796-8. PMID: 1136094Mobley DF, Guthrie TH. Renal cell carcinoma metastatic to urinary bladder. Urology. 1976 Jul;8(1):53-4. PMID: 941363Mobley DF. Phenoxybenzamine in the management of neurogenic vesical dysfunction. J Urol. 1976 Dec;116(6):737-8. PMID: 1003641Mobley DF. Studies in ureteral regeneration: replacement of a large segment of ureter with an in situ pedicle graft of proximal ureter. Invest Urol. 1977 Jan;14(4):269-73. PMID: 836464Nishimura T, Mobley DF, Carlton CE Jr. Clinical use of immunoelectrophoresis of split ejaculates. I. Variation of patterns due to antisera. Urology. 1977 Jan;9(1):39-41. PMID: 556657Nishimura T, Mobley DF, Carlton CE Jr. Immunoglobulin A in split ejaculates of patients with prostatitis. Urology. 1977 Feb;9(2):186-7. PMID: 841786Mobley DF. Bacterial prostatitis: treatment with carbenicillin indanyl sodium. Invest Urol. 1981 Jul;19(1):31-3. PMID: 7019153Kostas CI, Mobley DF, Rous SN, Schneider RE, Burt RA. Treatment of urinary tract infection with cephalexin. J Fam Pract. 1983 Jul;17(1):135, 138-40. No abstract available. PMID: 6864165David F. Mobley. Choosing a Penile Prosthesis. Medical Aspects of Human Sexuality. 1987;21(5)30-36.David F. Mobley. A New Simplified Technique for Implantation of Penile Prosthesis Reservoir. Colleagues in Urology. 1988;2(3):5.David F. Mobley. Penile Prosthesis Malfunction. Medical Aspects of Human Sexuality. 1990;24:69-71.David F. Mobley. Penile Curvature: Brief Communication. Medical Aspects of Human Sexuality. 1990;24:12-13.David F. Mobley, Ken Goldberg, and Steve Wilson. Management of Urinary Incontinence, Part I. Geriatric Medicine. 1991;10(9):19-35.David F. Mobley. Kidney Stones. Health and Fitness 1991;7(3):15.Mobley D, Raphaeli, A. Postcoital depression. Medical Aspects of Human Sexuality. 1992;26(2):6. (Q & A section)Baum N, Suarez G, Mobley D. Use of infra-pubic incision for insertion of Mentor Mark II inflatable penile prosthesis. Urology. 1992 May;39(5):436-8. PMID: 1580033Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. *The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185-91. PMID: 1383816 (Mobley in study group)Randrup E, Wilson S, Mobley D, Suarez G, Mekras G, Baum N. Clinical experience with Mentor Alpha I inflatable penile prosthesis. Report on 333 cases. Urology. 1993 Sep;42(3):305-8. PMID: 8379030Berger BM, Naadimuthu A, Boddy A, Fisher HA, McConnell JD, Milam D, Mobley D, Rajfer J. The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. *The Zanoterone Study Group. J Urol. 1995 Sep;154(3):1060-4. PMID: 7543598Mobley DF, Baum N. Interstitial cystitis. When urgency and frequency mean more than routine inflammation. Postgrad Med. 1996 May;99(5):201-4, 207-8, 214. PMID: 8650086Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol. 1997 Feb;157(2):525-30. PMID: 8996348Mobley DF, Kaplan S, Ice K, Gaffney M, Dias N. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies. Int J Clin Pract. 1997 Jul-Aug;51(5):282-8. PMID: 9489085Mobley, D.F., and Baum, N.H. Management of Impotence in the Geriatric Man. Clinical Geriatrics 1998;6(9):58-63.Mobley DF, Dias N, Levenstein M. Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia. Clin Ther. 1998 Jan-Feb;20(1):101-9. PMID: 9522108Mobley DF, Baum N. When patients request the impotence pill. Postgrad Med. 1998 Aug;104(2):55-8, 61-2, 65-6. Review. PMID: 9721579Mobley, D.F., Baum, N.H. Sildenafil in elderly men: Advice and caveats. Clinical Geriatrics 1999;7 (12):34-41.Anderson, R., Mobley, D.F., et. al. Comparative Efficacy and Safety of a Once-a-Day Controlled Release and an Immediate Release Oxybutyinin Chloride in the Treatment of Patients with Urge Urinary Incontinence. Journal of Urology. 1999;161(6):1809-12.Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999 Oct;54(4):662-9. PMID: 10510925 (Mobley in study group)Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. OROS Oxybutynin Study Group. J Urol. 1999 May;161(5):1551-5. PMID: 10210394 (Mobley in study group)Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 1999 Jun;161(6):1809-12. PMID: 10332441Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999 Oct;54(4):670-8. PMID: 10510926 (Mobley in study group)Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol. 2000 May;95(5):718-21. PMID: 10775736Dula E, Keating W, Siami PF, Edmonds A, O'neil J, Buttler S. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology. 2000 Jul;56(1):130-5. PMID: 10869641 (Mobley in study group)Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology. 2000 Oct 1;56(4):610-6. PMID: 11018616 (Mobley in study group) (Mobley in study group)Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001 Jun;57(6):1073-7. PMID: 11377309Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. ALFUS Study Group. Urology. 2001 Dec;58(6):953-9. PMID: 11744466 (Mobley in study group)Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J; Pless Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002 May;167(5):2105-8. PMID: 11956450Mobley, D., Baum, N. Management of Benign Prostatic Hyperplasia in the elderly patient. Geriatrics and Aging. 2004;7(6):23-28.Girard L, Baum N, Mobley D. Urinary Symptoms in patients with low back pain. J Pain Mgmt. 2013;6(2):105-16.Mobley DF, Baum N. Etiology, evaluation, and management of nocturia in elderly men and women. Postgrad Med. 2014 Mar;126(2):147-53. PMID: 24685979Baum N, Mobley D, Perito P. Improving operating efficiency with emphasis on prosthetic surgery. Asian J Androl. 2015 March;17:1-3. Epub ahead of print. doi: 10.4103/1008-682X.142146.Mobley D. Early history of inflatable penile prosthesis surgery: A view from someone who was there. Asian J Androl. Asian J Androl.?2015 Mar-Apr;17(2):225-9. doi: 10.4103/1008-682X.140962.Mobley?D,? HYPERLINK "" Feibus A,?Baum N. Benign prostatic hyperplasia?and urinary symptoms: Evaluation and treatment. Postgrad Med.?2015 Apr;127(3):301-7. doi: 10.1080/00325481.2015.1018799.Khera M, Baum N, MOBLEY D. Current management of erectile dysfunction. Accepted for publication, Post Grad Med 2016.Miller, S, MOBLEY, D, Watchful waiting vs. active surveillance: Whch treatment option is right for patients with localized prostate cancer? Urol & Neph. Open Access J. 2018;6(6)173-176.Publications In Progress:Mobley DF, Baum N. Smoking-It's Impact on Urological Conditions; A Review of the Literature. Urology. manuscript number: URL-D-15-00562. In review- Urology March 2015MOBLEY D, Baum N. Obesity and its impact on urological practice. In review for publication: Urology Practice. MOBLEY D, Baum,N. Hypochondria-when imagination becomes disease. Accepted for publication. Oschner Medical Journal 2018Books, Book Chapters and Reviews:BookDavid F. Mobley and Steven K. Wilson: Impotence, It's Reversible. Southwest Impotency Center. VanBuren AK 1990.Mobley D and Wilson SK. Reversing Impotence Forever! (The Male Sexual Well-Being Series). Edited by J Pepe and P Billac. Swan Pub Co (September 1995). ISBN-10: 0943629160; ISBN-13: 978-0943629162Book ChapterMobley, David and Baum, N.H. "Office Evaluation of the Impotent Man."?Male Infertility and Sexual Dysfunction. New York: Springer New York, 1997. 335-339.ReviewsDavid F. Mobley, J. Martinez. Two histologically different primary carcinomas of the lung. A review of the literature and presentation of a case. Cancer.?1968 Aug;22(2):287-92.Mobley DF. Chronic prostatitis. South Med J. 1974 Feb;67(2):219-24. Review. PMID: 4590619Baum N, Mobley DF, Carlton CE Jr. Ureteral replacements. Urology. 1975 Feb;5(2):165-71. Review. PMID: 1090050Other PublicationsTapesMobley, D. McMurray, James, Mulcahy, J: Helping Your Impotent Patients Make a Treatment Decision: Produced by American Medical Systems. 1989.Mobley, D., Baum, N., Gottesman, J.: Roundtable Forum on Practice Management: Prepared by American Medical Systems, 1993.Patient RelationsPhysician and Community RelationsManaging the Business Side of a Urology PracticeMobley, D., Baum, N., Eid, F ; A Primer on Marketing Your Practice Produced by American Medical Systems. April 1997BROCHURE:Mobley, D.F., Feinstein, C., Garber, B.: et. al. Building your Impotence Practice Through Medical Marketing. American Medical Systems 1997AbstractsAppell, R, Mobley, D.F. et. al.: Comparison of Urge Incontinence Treatments. Submitted for presentation at 1999 American Urological Association annual meeting. May 1-6, 1999. Dallas, TX.Appell, R., Mobley, D.F. et. al. Factors influencing patient Response to Controlled-Release Oxybutinin: A Meta-Analysis of Randomized Trials. 1999 American Urological Association annual meeting. May 1-6, Dallas, TXAnderson, R., Gittleman, M. Mobley, D.F. et al. The Effect of Age on Efficacy, Safety and Tolerability of Once-Daily Oxybutyin Chloride. 1999 American Urological Association annual meeting. May 1-6, Dallas, TXBrown J, Mobley D, et al. Efficacy and tolerability of once-daily oxybutinin chloride versus Ditropan in patients with urge or mixed urinary incontinence. 2015 American Urological Association annual meeting. May 2015. New Orleans, LA. PresentationsCarbenicillin in the Treatment of Acute and Chronic ProstatitisPoster Presentation, Scientific ExhibitWestern SectionAmerican Urological AssociationSalt Lake City UTJune 29-July 2, 1981(Second Place Award)Signature:Date: ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download